Executive interview – Immunicum

Published on 7 February 2020

Immunicum is a clinical-stage immunoncology company based in Stockholm, Sweden. The company is developing an allogeneic off-the-shelf dendritic cell immune activator (immune primer) for use in combination with tyrosine kinase inhibitors and checkpoint inhibitors in various solid tumour indications.

In this video, the company’s chief operating officer, Sijme Zeilemaker, explains the recently announced updated data from the lead Phase II MERECA trial, which the company presented at the ASCO-SITC Clinical Immuno-Oncology Symposium on 6 February 2020.

Share this with friends and colleagues